JP2017525766A - アルキル化インフルエンザワクチン - Google Patents

アルキル化インフルエンザワクチン Download PDF

Info

Publication number
JP2017525766A
JP2017525766A JP2017529592A JP2017529592A JP2017525766A JP 2017525766 A JP2017525766 A JP 2017525766A JP 2017529592 A JP2017529592 A JP 2017529592A JP 2017529592 A JP2017529592 A JP 2017529592A JP 2017525766 A JP2017525766 A JP 2017525766A
Authority
JP
Japan
Prior art keywords
alkylating agent
influenza
influenza virus
strain
influenza vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017529592A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017525766A5 (enExample
Inventor
ブルック ミルナー
ブルック ミルナー
ジョナサン ヘインズ
ジョナサン ヘインズ
スティーブン ハウザー
スティーブン ハウザー
ジャネット ポーリ
ジャネット ポーリ
Original Assignee
サノフィ パスツール インコーポレイテッド
サノフィ パスツール インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サノフィ パスツール インコーポレイテッド, サノフィ パスツール インコーポレイテッド filed Critical サノフィ パスツール インコーポレイテッド
Publication of JP2017525766A publication Critical patent/JP2017525766A/ja
Publication of JP2017525766A5 publication Critical patent/JP2017525766A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16061—Methods of inactivation or attenuation
    • C12N2760/16063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2017529592A 2014-08-18 2015-08-18 アルキル化インフルエンザワクチン Pending JP2017525766A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462038753P 2014-08-18 2014-08-18
US62/038,753 2014-08-18
PCT/US2015/045689 WO2016028776A1 (en) 2014-08-18 2015-08-18 Alkylated influenza vaccines

Publications (2)

Publication Number Publication Date
JP2017525766A true JP2017525766A (ja) 2017-09-07
JP2017525766A5 JP2017525766A5 (enExample) 2018-09-20

Family

ID=54008038

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017529592A Pending JP2017525766A (ja) 2014-08-18 2015-08-18 アルキル化インフルエンザワクチン

Country Status (9)

Country Link
US (1) US10124056B2 (enExample)
EP (1) EP3182998A1 (enExample)
JP (1) JP2017525766A (enExample)
KR (1) KR20170042605A (enExample)
CN (1) CN106794241A (enExample)
AU (1) AU2015305690A1 (enExample)
CA (1) CA2957570A1 (enExample)
SG (1) SG11201701279VA (enExample)
WO (1) WO2016028776A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7403733B2 (ja) * 2017-09-04 2023-12-25 国立感染症研究所長 インフルエンザｈａスプリットワクチンの製造方法
WO2019045090A1 (ja) * 2017-09-04 2019-03-07 公益財団法人ヒューマンサイエンス振興財団 インフルエンザｈａスプリットワクチンの製造方法
CN111511800B (zh) 2017-10-30 2023-11-28 武田药品工业株式会社 灭活脂包膜病毒的环境相容性去污剂
TW202011986A (zh) 2018-07-23 2020-04-01 公益財團法人日本健康科學振興財團 包含流感疫苗之組合物
PH12021552094A1 (en) 2019-03-04 2022-05-30 Japan As Represented By Director General Of Nat Institute Of Infectious Diseases Method for preparing influenza ha split vaccine
CN112618709B (zh) * 2019-09-24 2023-11-03 华南理工大学 一种猪口服接种疫苗缓释佐剂及其制备方法与应用
CN112708599B (zh) * 2019-10-25 2022-02-18 中国农业大学 一株禽流感病毒疫苗株及其应用
US12428372B2 (en) 2022-04-14 2025-09-30 Saudi Arabian Oil Company ODSO acid medium, ODSO acid mixture medium, and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060051742A1 (en) * 2004-03-17 2006-03-09 Kapteyn Johan C Novel assay for the separation and quantification of hemagglutinin antigens
JP2006257102A (ja) * 1997-12-26 2006-09-28 Jean-Francois Zagury 抗レトロウイルス免疫原、調製および使用
JP2008530067A (ja) * 2005-02-11 2008-08-07 ナショナル インスティテュート フォー バイオロジカル スタンダーズ アンド コントロール（エヌアイビーエスシー） 新規無毒化方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62221636A (ja) 1986-03-20 1987-09-29 Chemo Sero Therapeut Res Inst Ｂ型肝炎ウイルス抗原蛋白の可溶化方法
JPWO2003014338A1 (ja) 2001-08-02 2004-11-25 アンジェスＭｇ株式会社 不活性化ウイルスエンベロープの製造方法
EP1481985A1 (en) 2003-05-28 2004-12-01 Innogenetics N.V. Modified hepatitis C virus (HCV) NS3 for medical treatment
CN101161285A (zh) * 2007-09-06 2008-04-16 上海荣盛生物技术有限公司 流感病毒裂解疫苗
CN102858961A (zh) 2010-05-03 2013-01-02 葛兰素史密丝克莱恩生物有限公司 新方法
WO2011154976A2 (en) 2010-06-08 2011-12-15 Panacea Biotec Limited Improved influenza vaccine
CN102406931B (zh) * 2011-11-25 2014-02-05 成都康华生物制品有限公司 大流行流感病毒裂解疫苗

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006257102A (ja) * 1997-12-26 2006-09-28 Jean-Francois Zagury 抗レトロウイルス免疫原、調製および使用
US20060051742A1 (en) * 2004-03-17 2006-03-09 Kapteyn Johan C Novel assay for the separation and quantification of hemagglutinin antigens
JP2008530067A (ja) * 2005-02-11 2008-08-07 ナショナル インスティテュート フォー バイオロジカル スタンダーズ アンド コントロール（エヌアイビーエスシー） 新規無毒化方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J.PHARM.SCI.2014 MAR,103(3),P.821-827, JPN6019020637, ISSN: 0004182800 *

Also Published As

Publication number Publication date
US20160045590A1 (en) 2016-02-18
CA2957570A1 (en) 2016-02-25
WO2016028776A1 (en) 2016-02-25
SG11201701279VA (en) 2017-03-30
EP3182998A1 (en) 2017-06-28
KR20170042605A (ko) 2017-04-19
US10124056B2 (en) 2018-11-13
CN106794241A (zh) 2017-05-31
AU2015305690A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
US10124056B2 (en) Alkylated influenza vaccines
US10130700B2 (en) Polyvalent influenza virus-like particles (VLPS) and use as vaccines
CN107949636B (zh) 活减毒病毒以及生产和使用方法
JP2018134107A (ja) インフルエンザウイルスワクチン及びその使用
US20130209499A1 (en) Vaccines for use in the prophylaxis and treatment of influenza virus disease
WO2019032463A1 (en) IMMUNOGENIC COMPOSITIONS COMPRISING INFLUENZA VIRUS AND AS01 CHIMERIC POLYPEPTIDES OF HEMAGGLUTININ AND USES THEREOF
US20130315955A1 (en) Stability and potency of hemagglutinin
JP7479424B2 (ja) 改変インフルエンザヘマグルチニンポリペプチドの修飾
US11369675B2 (en) Broadly protective inactivated influenza virus vaccine
WO2008157203A2 (en) Methods of protecting animals from avian influenza infection
CA3064760A1 (en) Universal influenza vaccine
Nuwarda et al. An Overview of Influenza Viruses and Vaccines. Vaccines 2021, 9, 1032
RU2323740C1 (ru) ШТАММ "НОВОСИБИРСКИЙ" ВИРУСА ГРИППА ПТИЦ Influenzae virus avicum ДЛЯ КОНТРОЛЯ ИММУНОГЕННОЙ И АНТИГЕННОЙ АКТИВНОСТИ ВАКЦИН И ИЗГОТОВЛЕНИЯ БИОПРЕПАРАТОВ ДЛЯ ДИАГНОСТИКИ И СПЕЦИФИЧЕСКОЙ ПРОФИЛАКТИКИ ГРИППА ПТИЦ
CN115103905B (zh) 表达α-1,3-半乳糖基转移酶的重组病毒及其用途
US20230055468A1 (en) Broadly reactive viral antigens as immunogens, compositions and methods of use thereof
EA044592B1 (ru) Модификация сконструированных полипептидов гемагглютинина вируса гриппа

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180807

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190605

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191225